ライフサイエンスコーパス: intrahepatic

1 VAT (-22%), intrahepatic (-29%), and intrapericardial (-11%) fats de

2 sed case-control study, 2395 CCA cases (1169 intrahepatic, 995 perihilar, and 231 distal) seen at the

3 t that abnormal AAT protein conformation and intrahepatic accumulation have broad effects on metaboli

4 Intrahepatic accumulation of bile acids (BAs) causes hep

5 antagonist, failed to prevent pre-mNK cells' intrahepatic accumulation.

6 lectrin-mediated cross-presentation supports intrahepatic adaptive antiviral immune responses and may

7 Moreover, the renal excretion kinetic and intrahepatic albumin binding affinity of CyG can further

8 ility of invasion and migration in vitro and intrahepatic and distal lung metastasis in vivo of HCC c

9 elial cells, named cholangiocytes, that line intrahepatic and extrahepatic bile ducts, contribute sub

10 dysplastic morphology and expansion of both intrahepatic and extrahepatic biliary cells, and ultimat

11 aphy (MRCP) is the best test to evaluate the intrahepatic and extrahepatic biliary tract, and MRI als

12 ession levels were measured in the following intrahepatic and extrahepatic cholangiocarcinoma (CCA) c

13 ghtly controlled event involving coordinated intrahepatic and extrahepatic regulation.

14 ance (tolerance tests) were achieved in both intrahepatic and intraomental sites in rats.

15 opancreatic ductal (HPD) system connects the intrahepatic and intrapancreatic ducts to the intestine

16 c inflammation and fibro-obliteration of the intrahepatic and/or extrahepatic bile ducts.

17 nstrates vasculature changes associated with intrahepatic angiogenesis and portal hypertension during

18 concomitant decreases in AST/ALT suggest an intrahepatic anti-inflammatory effect.

19 Group 1 rats received intrahepatic arterial injection of PEG-HAuNS and ethiodi

20 activation and spontaneous IgG production by intrahepatic B cells.

21 ansport and bile acid metabolism, leading to intrahepatic bile accumulation in SCD mouse liver.

22 R-dependent impaired bile secretion promotes intrahepatic bile accumulation, which contributes to hep

23 erozygous mice (Jag1(+/-) ) exhibit impaired intrahepatic bile duct (IHBD) development, decreased SOX

24 Preoperative knowledge of intrahepatic bile duct (IHD) anatomy is critical for pla

25 Intrahepatic bile duct anatomy is complex with many comm

26 opment of strategies to block progression of intrahepatic bile duct injury in patients with BA.

27 ed hepatic IL-17A production and ameliorated intrahepatic bile duct injury.

28 llowing bile duct ligation (BDL), increasing intrahepatic bile duct mass (IBDM) and fibrosis.

29 ression and MC presence or activation; large intrahepatic bile duct mass, inflammation and senescence

30 While intrahepatic bile duct proliferation is universal at dia

31 Small and large intrahepatic bile ducts consist of small and large chola

32 Adjacent intrahepatic bile ducts were dilated.

33 The bile duct wall enhancement, intrahepatic bile ducts, and gallbladder were also evalu

34 uction of the extrahepatic biliary tract and intrahepatic bile ducts.

35 biliary glands within extrahepatic and large intrahepatic bile ducts.

36 ompensatory proliferation of hepatocytes and intrahepatic biliary cells, thus impeding HCC developmen

37 nts with biliary atresia (BA), the extent of intrahepatic biliary fibrosis negatively correlates with

38 phocyte responses orchestrate progression of intrahepatic biliary injury in this disease.

39 nd HuH-28, as well as the nonmalignant human intrahepatic biliary line, H69.

40 inistration of GnRH to normal rats increased intrahepatic biliary mass (IBDM) and hepatic fibrosis.

41 Intrahepatic biliary mass was detected by cytokeratin-19

42 in increased cholangiocyte proliferation and intrahepatic biliary mass, liver damage, and inflammatio

43 e produced a crowded branching defect in the intrahepatic biliary network and influenced actin dynami

44 ase 5 (Cdk5) led to reduced branching in the intrahepatic biliary network in zebrafish.

45 The intrahepatic biliary network is a highly branched three-

46 insights into branching morphogenesis of the intrahepatic biliary network.

47 The pathogenesis of intrahepatic biliary stricture formation in patients wit

48 Our primary outcome was development of intrahepatic biliary strictures consistent with IC.

49 oposed role in the normal development of the intrahepatic biliary system.

50 An abdominal CT demonstrated a dilated intrahepatic biliary tree with left proximal intrahepati

51 limp-1(hi)Hobit(lo) T cells found within the intrahepatic but not the circulating memory CD8 T cell p

52 olesterolemia induced the differentiation of intrahepatic, but not intrasplenic, Th17 cells in wild-t

53 iated with shorter survival of patients with intrahepatic CCA (HR, 4.2; 95% CI: 1.1-14.1; P = 0.04).

54 NAFLD and CCA, stratifying by its subtypes; intrahepatic CCA (iCCA), and extrahepatic CCA (eCCA).

55 c CCA, but there are no data for its role in intrahepatic CCA (iCCA).

56 Noninvasive differential diagnosis between intrahepatic CCA and hepatocellular carcinoma (HCC) is s

57 3 expression was increased in both hilar and intrahepatic CCA samples as well as in CCA cell lines.

58 of myeloid cell infiltration in HCC, NET and intrahepatic CCA tumors further established that the fre

59 0.904 for HCC versus control, and 0.894 for intrahepatic CCA versus HCC.

60 For intrahepatic CCA, EUS detected a higher percentage of RL

61 is currently in clinical phase 2 trials for intrahepatic CCA.

62 ic CCA, but there is no data for its role in intrahepatic CCA.

63 Four invasive PDACs and 2 intrahepatic CCAs from the same patients as the IOPNs, w

64 re found in corresponding invasive PDACs and intrahepatic CCAs, as well as in matched pancreatic cyst

65 Clearances of intrahepatic cccDNA and/or HBsAg are critical endpoints

66 dd)PCR assays were used to quantify residual intrahepatic cccDNA in liver biopsies from 56 chronicall

67 The assessment of residual intrahepatic cccDNA levels and activity after long-term

68 t and retention and enhances polarization of intrahepatic CD4 cells toward Th17 cells via type 17 cyt

69 tabolism in NAFLD causes a selective loss of intrahepatic CD4(+) but not CD8(+) T lymphocytes, leadin

70 increased frequency of IL-17(+) cells among intrahepatic CD4(+) T cells and higher Th17/rTreg and Th

71 arked by an increase in IL-17(+) cells among intrahepatic CD4(+) T cells.

72 almitic acid, and mediates selective loss of intrahepatic CD4(+) T lymphocytes.

73 Liver disease elicits alterations in the intrahepatic CD4(+) T-cell compartment that suppress T-c

74 in 10), which correlated with populations of intrahepatic CD4+ T cells (CD45RO+PD-1+).

75 ls and expression of inhibitory molecules on intrahepatic CD8(+) T cells.

76 Exhausted intrahepatic CD8(+) T-cell targeting-conserved epitopes

77 between serum HBsAg levels and impairment of intrahepatic CD8+ T cells has not been established.

78 infection can be attributed to nonfunctional intrahepatic CD8+ T-cell responses.

79 nfection coincides with a vigorous recall of intrahepatic cellular responses.

80 liver disease and nonspecific cirrhosis, to intrahepatic cholangiocarcinogenesis together with geogr

81 ), non-colorectal liver metastases (7%), and intrahepatic cholangiocarcinoma (6%).

82 equencing of 133 combined hepatocellular and intrahepatic cholangiocarcinoma (cHCC-ICC) cases, includ

83 Intrahepatic cholangiocarcinoma (ICC) accounts for 12% o

84 Intrahepatic cholangiocarcinoma (ICC) and hepatocellular

85 rom combined hepatocellular liver cancer and intrahepatic cholangiocarcinoma (ICC) has increased and

86 We aimed to examine the burden of intrahepatic cholangiocarcinoma (ICC) in Thailand and id

87 Intrahepatic cholangiocarcinoma (ICC) is a highly malign

88 Intrahepatic cholangiocarcinoma (ICC) is a severe malign

89 Intrahepatic cholangiocarcinoma (ICC) is asevere maligna

90 and 87.5%, 70.0% and 70.0% for patients with intrahepatic cholangiocarcinoma (ICC) respectively.

91 232R) of PTPN3, a frequent mutation found in intrahepatic cholangiocarcinoma (ICC), disables its role

92 In patients with intrahepatic cholangiocarcinoma (ICC), the oncologic ben

93 on and aggressive malignancy of mass-forming intrahepatic cholangiocarcinoma (ICC), we modeled ICC de

94 Early and differential diagnosis of intrahepatic cholangiocarcinoma (iCCA) and hepatocellula

95 Intrahepatic cholangiocarcinoma (iCCA) has over the last

96 Intrahepatic cholangiocarcinoma (iCCA) is a contraindica

97 Intrahepatic cholangiocarcinoma (iCCA) is the second mos

98 er comprises hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and other rare t

99 markers made progresses slowly compared with intrahepatic cholangiocarcinoma because of surgical comp

100 f cHCC-ICC with hepatocellular carcinoma and intrahepatic cholangiocarcinoma revealed that combined a

101 occur in approximately 13% of patients with intrahepatic cholangiocarcinoma, a relatively uncommon c

102 ondary glioblastoma, acute myeloid leukemia, intrahepatic cholangiocarcinoma, and chondrosarcomas, le

103 ly encompassing hepatocellular carcinoma and intrahepatic cholangiocarcinoma, has become the second l

104 up to 25% of cholangiocarcinomas, especially intrahepatic cholangiocarcinoma.

105 % were hepatocellular carcinoma and 20% were intrahepatic cholangiocarcinoma.

106 , increased cholangiocyte proliferation, and intrahepatic cholangiocarcinoma.

107 About 15% of intrahepatic cholangiocarcinomas (ICCs) express constitu

108 itized both EHCs and the otherwise resistant intrahepatic cholangiocytes to the toxin, whereas replen

109 pha-1 antitrypsin deficiency (A1AT), chronic intrahepatic cholestasis (CIC), and Alagille syndrome (A

110 Intrahepatic cholestasis (IHC) was observed in 4.9% of I

111 holangiopathies such as progressive familial intrahepatic cholestasis and primary sclerosing cholangi

112 idered as an additional progressive familial intrahepatic cholestasis gene.

113 the Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis in the Childhood Liver Disease

114 Intrahepatic cholestasis of pregnancy (ICP) affects 1/14

115 Intrahepatic cholestasis of pregnancy (ICP) can predispo

116 Intrahepatic cholestasis of pregnancy (ICP) causes incre

117 Intrahepatic cholestasis of pregnancy (ICP) is a pregnan

118 pruritus of the skin is an early symptom of intrahepatic cholestasis of pregnancy (ICP) or due to be

119 Women with intrahepatic cholestasis of pregnancy (ICP), a disorder

120 tch and lower endogenous serum bile acids in intrahepatic cholestasis of pregnancy (ICP).

121 cirrhosis was independently associated with intrahepatic cholestasis of pregnancy (relative risk [RR

122 isk of stillbirth is increased in women with intrahepatic cholestasis of pregnancy and singleton preg

123 Inclusion criteria were studies defining intrahepatic cholestasis of pregnancy based upon pruritu

124 e for the aggregate data meta-analysis (5557 intrahepatic cholestasis of pregnancy cases and 165 136

125 Stillbirth occurred in 45 (0.83%) of 4936 intrahepatic cholestasis of pregnancy cases and 519 (0.3

126 was three (0.13%; 95% CI 0.02-0.38) of 2310 intrahepatic cholestasis of pregnancy cases in women wit

127 165 136 controls), and 27 provided IPD (5269 intrahepatic cholestasis of pregnancy cases).

128 Because most women with intrahepatic cholestasis of pregnancy have bile acids be

129 to quantify the adverse perinatal effects of intrahepatic cholestasis of pregnancy in women with incr

130 Intrahepatic cholestasis of pregnancy is associated with

131 reporting perinatal outcomes for women with intrahepatic cholestasis of pregnancy when serum bile ac

132 gement of acute fatty liver of pregnancy and intrahepatic cholestasis of pregnancy, and their impact

133 Intrahepatic cholestasis of pregnancy, characterised by

134 We recruited women with intrahepatic cholestasis of pregnancy, who were aged 18

135 uce adverse perinatal outcomes in women with intrahepatic cholestasis of pregnancy.

136 ces adverse perinatal outcomes in women with intrahepatic cholestasis of pregnancy.

137 rea cycle disorders and progressive familial intrahepatic cholestasis type 2.

138 ary diseases, including progressive familial intrahepatic cholestasis type 3 (PFIC3), a rare disease

139 Progressive familial intrahepatic cholestasis type 3 (PFIC3), an inherited ju

140 e the tumorigenicity of progressive familial intrahepatic cholestasis type 3 and, with further refine

141 Progressive familial intrahepatic cholestasis type 3 is caused by biallelic v

142 ariations identified in progressive familial intrahepatic cholestasis type 3 patients.

143 tations in ATP8B1 cause progressive familial intrahepatic cholestasis type1 in humans, which is chara

144 fferent genes can cause progressive familial intrahepatic cholestasis, but known genes cannot account

145 h Alagille syndrome (ALGS), 16 with familial intrahepatic cholestasis-1 (FIC1), 18 with bile salt exp

146 predisposed to adolescent development of an intrahepatic cholestasis-like condition with attendant h

147 asis characterized by a progressive familial intrahepatic cholestasis-like phenotype with normal seru

148 s in five patients with progressive familial intrahepatic cholestasis-like phenotype with normal seru

149 ysis of nontransplant surgical approaches to intrahepatic cholestasis.

150 DXA) analysis was performed in children with intrahepatic cholestatic diseases who were enrolled in t

151 Statins have beneficial effects on intrahepatic circulation and decrease portal hypertensio

152 mulation and identified the trigger of rapid intrahepatic coagulation after PHx.

153 PHx in wild-type mice triggered rapid intrahepatic coagulation, evidenced by intrahepatic fibr

154 of murine liver with adenovirus, a model for intrahepatic cross-presentation, confirms hepatocytes di

155 Consequently, intrahepatic cytokine and chemokine release, macrovesicu

156 ers by RNA interference resulted in impaired intrahepatic development.

157 Very little is known about the intrahepatic distribution of HBV cccDNA in infected pati

158 and retaining functions of primary extra- or intrahepatic duct cholangiocytes within 2 weeks of isola

159 Portal venous pressure and intrahepatic endothelial dysfunction might account for t

160 ebrand factor antigen levels as a marker for intrahepatic endothelial dysfunction.

161 , and the GCKR rs1260326 SNPs in determining intrahepatic fat accumulation (P < 0.05).

162 o the adipose tissue and the liver regulates intrahepatic fat storage.

163 es were significantly correlated with higher intrahepatic fat stores.

164 ther adjusted for weight loss, losing VAT or intrahepatic fat was independently associated with impro

165 Body fat and intrahepatic fat were detected by magnetic resonance ima

166 eased hepatic de novo lipogenesis, decreased intrahepatic fatty acid oxidation, and inadequate increa

167 ovel mechanism whereby coagulation-dependent intrahepatic fibrin(ogen) deposition drives platelet acc

168 Intrahepatic fibrin(ogen) deposition was abolished in mi

169 Moreover, increased intrahepatic fibrin(ogen) deposition was evident in live

170 Thrombin-dependent intrahepatic fibrin(ogen) deposition was recently report

171 rapid intrahepatic coagulation, evidenced by intrahepatic fibrin(ogen) deposition.

172 s to liver regeneration primarily by driving intrahepatic fibrin(ogen) deposition.

173 nt was also associated with replenishment of intrahepatic glucose due to enhanced gluconeogenesis and

174 Altered intrahepatic glucose signaling in type 2 diabetes associ

175 in vitro knockdown of TTK effectively blocks intrahepatic growth of human HCC xenografts.

176 The degree of integration of intrahepatic HBV DNA in the HBeAg-negative stage may be

177 dulated to allow control and/or clearance of intrahepatic HBV DNA.

178 h settings so far, aim to quantify levels of intrahepatic HBV replication.

179 not negligible and transcriptionally active intrahepatic HBV reservoir (circular covalently closed D

180 ociated with an increase in the frequency of intrahepatic HBV-specific CD8(+) T cells and a transient

181 upport the prognostic importance of treating intrahepatic HCC even in patients with metastatic diseas

182 ular carcinoma (HCC) is mainly determined by intrahepatic HCC progression, local treatment with TACE

183 intrahepatic biliary tree with left proximal intrahepatic hyperdensities, as well as a 3 cm hepatocel

184 A methylation of SLC22A1 were analyzed using intrahepatic (iCCA) and extrahepatic (eCCA) biopsies (Co

185 ive players in determining the nature of the intrahepatic immune microenvironment.

186 e important causes of human disease, but the intrahepatic immune response to hepatitis viruses is poo

187 gt1 and gt3 infections do not elicit innate intrahepatic immune responses and remain highly sensitiv

188 Intrahepatic in utero injections of a beta globin-expres

189 , we postulated that Mincle signaling drives intrahepatic inflammation and liver injury in Con A hepa

190 e, proinflammatory microparticles that cause intrahepatic inflammation, vasoconstriction, and extrahe

191 ngraftment was associated with low levels of intrahepatic inflammatory cells and mediators of islet d

192 RIF) was a central mediator of the resulting intrahepatic inflammatory response that was independent

193 Herein, we describe an original method of intrahepatic injection into adult NOD.Cg-Prkdc(scid)Il2r

194 Intrahepatic injection of HB cell lines leads to liver t

195 e using minimally invasive ultrasound-guided intrahepatic injection.

196 ormed on HCC model implanted in nude mice by intrahepatic injection.

197 EV infections in humanized mice and modelled intrahepatic interferon stimulated gene (ISG) responses.

198 s superior to the low-fat diet in decreasing intrahepatic, intrapericardial, and pancreatic fats (P<0

199 Since 2000, intrahepatic islet transplantation has proven efficaciou

200 prerequisite is currently incompatible with intrahepatic islet transplantation.

201 We explored the role of intrahepatic LCN2 in human alcoholic hepatitis (AH) with

202 crosis factor alpha and interleukin 2 at the intrahepatic level significantly more than HCV-specific

203 ally, the lack of stabilin-1 led to elevated intrahepatic levels of the profibrogenic chemokine CCL3

204 Secondary outcome measures were intrahepatic lipid (IHL) content, body composition, rest

205 antly greater visceral adipose tissue (VAT), intrahepatic lipid (IHL), plasma free fatty acids, adipo

206 ter suppression rates of lipolysis and lower intrahepatic lipid and plasma triacylglycerol concentrat

207 estriction to allow an effective decrease of intrahepatic lipid component, and despite that evidence

208 show that Plin5 is an important modulator of intrahepatic lipid metabolism and suggest that the incre

209 ristics (e.g., parity, body composition, and intrahepatic lipid).

210 emic control and a reduction in body weight, intrahepatic lipid, and visceral adipose tissue in patie

211 capacity have profound effects on regulating intrahepatic lipids and mediating susceptibility for hep

212 pared with caloric restriction on regulating intrahepatic lipids and steatosis risk; 3) the effects o

213 Hepatic steatosis, the excess storage of intrahepatic lipids, is a rampant clinical problem assoc

214 vity of hepatic adipose triglyceride lipase, intrahepatic lipolysis, hepatic acetyl-CoA content and p

215 For colorectal liver metastasis (CRLM), intrahepatic lymph invasion and lymph node metastasis ar

216 Furthermore, when splenic and intrahepatic lymphocytes from IFN-alpha- and IL-15-treat

217 FACS analysis was performed on PBMCs and intrahepatic lymphocytes.

218 th sofosbuvir and velpatasvir, we found that intrahepatic MAIT cells are activated by monocyte-derive

219 Recently, many drugs (mainly targeting intrahepatic mechanisms) have shown promise in preclinic

220 hat implicate a role for GKRP in maintaining intrahepatic metabolite homeostasis.

221 centric hepatocellular carcinomas (HCC) from intrahepatic metastases.

222 icantly reduced CCA cell growth in vitro and intrahepatic metastasis in vivo.

223 ens, especially in portal vein metastasis or intrahepatic metastasis, compared to normal tissues.

224 oavailability, HSC deactivation, and reduced intrahepatic microthrombosis.

225 educed fibrin deposition, suggesting reduced intrahepatic microthrombosis.

226 tumor progression, characterized by reduced intrahepatic numbers of invariant NKT and CD4(+) T cells

227 0.27-0.42), and 0.29 (95% CI 0.19-0.44) for intrahepatic, perihilar, and distal CCA, respectively (P

228 tients; 24 (15%), 124 (79%), and 9 (6%) with intrahepatic, perihilar, and distal CCA, respectively.

229 tients; 24 (15%), 124 (79%), and 9 (6%) with intrahepatic, perihilar, and distal CCA, respectively.

230 The intrahepatic periportal expansion of the PROM1(pos) cell

231 ibrinogen depletion with ancrod reduced both intrahepatic platelet accumulation and hepatocyte prolif

232 ntributes to liver regeneration by promoting intrahepatic platelet accumulation and identified the tr

233 APT reduced intrahepatic platelet accumulation and the frequency of

234 to liver regeneration after PHx by promoting intrahepatic platelet accumulation.

235 nsation in patients undergoing Trans jugular intrahepatic Porto systemic shunts (TIPS) procedure (1).

236 A preemptive transjugular intrahepatic portosystemic shunt (p-TIPS) has been shown

237 e the feasibility and safety of transjugular intrahepatic portosystemic shunt (TIPS) as a treatment f

238 <12 mm Hg after placement of a transjugular intrahepatic portosystemic shunt (TIPS) correlates with

239 early liver failure (ELF) after transjugular intrahepatic portosystemic shunt (TIPS) creation in pati

240 Background Transjugular intrahepatic portosystemic shunt (TIPS) creation is an a

241 e efficacy and complications of transjugular intrahepatic portosystemic shunt (TIPS) creation perform

242 of study patients who underwent transjugular intrahepatic portosystemic shunt (TIPS) creation, regard

243 covered stent and bare stent in transjugular intrahepatic portosystemic shunt (TIPS) for cirrhotic po

244 hnical success, and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) in a series of p

245 The efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) in this populati

246 Transjugular intrahepatic portosystemic shunt (TIPS) is now a standar

247 ex embolization with or without transjugular intrahepatic portosystemic shunt (TIPS) placement in pat

248 tic blood flow before and after transjugular intrahepatic portosystemic shunt (TIPS) placement.

249 ta are available on the role of transjugular intrahepatic portosystemic shunt (TIPS) with covered ste

250 T) has been mainly treated with transjugular intrahepatic portosystemic shunt (TIPS).

251 ortality in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS).

252 ative portal vein embolization, transjugular intrahepatic portosystemic shunt placement, balloon retr

253 controversy over the ability of transjugular intrahepatic portosystemic shunts (TIPS) to increase sur

254 controversy over the ability of transjugular intrahepatic portosystemic shunts (TIPS) to increase sur

255 f HBV-specific naive CD8+ T cells undergoing intrahepatic priming.

256 2 largest liver metastases predicted time to intrahepatic progression (P = 0.013; HR, 0.21; 95% CI, 0

257 ival, progression-free survival, and time to intrahepatic progression after radioembolization for liv

258 ival, progression-free survival, and time to intrahepatic progression were among other factors correl

259 HBV DNA levels in serum correlated with the intrahepatic proportion of linear HBV DNA.

260 roscopic RFA (L-RFA) have been used to treat intrahepatic recurrent small hepatocellular carcinoma (H

261 erved that hypercholesterolemia elevated the intrahepatic regulatory T (Treg) cell population and inc

262 c infection, characterized by high levels of intrahepatic regulatory T cells and expression of inhibi

263 ons that lower portal pressure by decreasing intrahepatic resistance.

264 CC in male mice with substantially increased intrahepatic retention of hydrophobic BAs and decreased

265 ant cholestasis with substantially increased intrahepatic retention of hydrophobic BAs.

266 Intrahepatic sequestration of platelets was significantl

267 lysis revealed a highly connected network of intrahepatic signaling and disruption of vascular signal

268 atic stellate cells (HSCs) serve as a hub of intrahepatic signaling via HSC-derived stellakines and t

269 ables were compared between tumors that were intrahepatic, small (<7 cm), and solitary (ISS) and thos

270 iRNAs to already tumor-bearing liver, limits intrahepatic spread of liver cancer cells.

271 indicates that exercise powerfully regulates intrahepatic storage of fat and risk for steatosis.

272 ic cholangiopathy (IC), a disease of diffuse intrahepatic stricturing limits broader DCDD use.

273 ary stricture, of which 88 (11.8%) exhibited intrahepatic structuring consistent with IC.

274 y dual immunohistochemistry, we affirm human intrahepatic T cell infiltrate includes CCR6(+)CD4(+) an

275 In HCV, intrahepatic T cells express chemokine receptors (CCRs),

276 Flow cytometry of intrahepatic T cells isolated from liver biopsy led to t

277 ults elucidate a new mechanism that controls intrahepatic T-cell differentiation during atheroscleros

278 n hypercholesterolemic Ldlr(-/-) mice led to intrahepatic Th1 cell differentiation and CD11b(+)CD11c(

279 Intrahepatic transcatheter infusion procedures were perf

280 woodchucks; the identification of a baseline intrahepatic transcriptional signature associated with r

281 However, relative to the conventional intrahepatic transplantation site, the subcutaneous site

282 ys, a number comparable to that required for intrahepatic transplantation; in the absence of oxygen t

283 y and cardiovascular disease and begins with intrahepatic triacylglycerol accumulation.

284 n in 3 groups: (a) lean subjects with normal intrahepatic triglyceride (IHTG) and glucose tolerance (

285 The cut-off point of intrahepatic triglyceride (IHTG) content to define nonal

286 BACKGROUNDAn increase in intrahepatic triglyceride (IHTG) is the hallmark feature

287 ma Fgf21 level significantly correlated with intrahepatic triglyceride content.

288 a high-fat diet, Plin5(LKO) mice accumulated intrahepatic triglyceride, without significant changes i

289 (NEFA), the main substrate for synthesis of intrahepatic triglycerides (IHTG).

290 In metastatic HCC, treatment of intrahepatic tumor by TACE may be associated with improv

291 CI: 18, 47) of 40 completely ablated tumors, intrahepatic tumor recurrence was observed at 2-18 month

292 nths on average to assess complete ablation, intrahepatic tumor recurrence, and complications.

293 of (90)Y radioembolization in patients with intrahepatic tumors from pretherapeutic baseline paramet

294 MRI showed large intrahepatic tumors with active neovascularization.

295 aarterial administration for hepatic tumors, intrahepatic tumors, and uninvolved background organs (s

296 nts, which were mainly mediated by increased intrahepatic tumour-growth factor (TGF)-beta because blo

297 In cirrhosis, increased intrahepatic vascular resistance (IHVR) is the primary f

298 PH results initially from increased intrahepatic vascular resistance.

299 l resolution provides a means for monitoring intrahepatic virological events in chronic HBV infection

300 GS-9688 treatment reduced intrahepatic WHV RNA and DNA levels by >95% in animals i